Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ: ALNY · Real-Time Price · USD

165.04

+8.39 (5.36%)

At close: Nov 13, 2026, 4:00 PM EST

165.91

+0.87 (0.53%)

After-hours: Nov 13, 2026, 7:59 PM EST

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
AMVUTTRA Revenue	3.86B	2.31B	970.45M
ONPATTRO Revenue	90.23M	172.79M	252.86M
GIVLAARI Revenue	340.44M	308.49M	255.87M
OXLUMO Revenue	205.59M	191.44M	167.05M
Total Product Revenue	4.49B	2.99B	1.65B
Roche - Collaboration Revenue	149.59M	394.88M	119.49M
Regeneron Pharmaceuticals - Collaboration Revenue	91.52M	113.96M	302.80M
Novartis AG - Collaboration Revenue	-	-	79.76M
Other - Collaboration Revenue (Post-FY2022)	545.00K	44.53M	8.18M
Total Collaboration Revenue	241.66M	553.37M	510.22M
Royalty Revenue	276.68M	174.02M	91.79M
Revenue (Other)	-241.66M	-553.37M	-510.22M
Revenue (Total)	5.01B	3.71B	2.25B